Anti-RNase L – Purified in vivo GOLD™ Functional Grade

Mouse IgG1 GOLD, Clone hksp OR Mouse IgG1 GOLD, Clone hksp84

Purified, full-length, recombinant, human RNaseL produced in insect cells.

This monoclonal antibody is aseptically packaged and formulated in 0.01 M phosphate buffered saline (150 mM NaCl) PBS pH 7.2 - 7.4 with no carrier protein, potassium, calcium or preservatives added. Due to inherent biochemical properties of antibodies, certain products may be prone to precipitation over time. Precipitation may be removed by aseptic centrifugation and/or filtration.

Functional grade preclinical antibodies are manufactured in an animal free facility using in vitro cell culture techniques and are purified by a multi-step process including the use of protein A or G to assure extremely low levels of endotoxins, leachable protein A or aggregates.

Functional grade preclinical antibodies may be stored sterile as received at 2-8°C for up to one month. For longer term storage, aseptically aliquot in working volumes without diluting and store at ≤ -70°C. Avoid Repeated Freeze Thaw Cycles.

Next Day 2-8°C

Clone 2E9 recognizes an epitope on human/hamster/primate RNaseL.

RNase L antibody, clone 2E9, recognizes the interferon (IFN)-inducible 2-5A-dependent ribonuclease L (RNase L), an endoribonuclease involved in antiviral signaling. It is widely expressed as a latent monomer in most mammalian tissues¹. 2’,5’-oligoadenylate synthetase (OAS) is expressed following viral infection and exposure to IFN2. OAS proteins are activated by dsRNA, resulting in the production of 2’,5’-linked oligoadenylates (2-5A), which bind to latent RNase L, inducing dimerization and activation2. RNase L inhibits viral replication by cleaving viral and ribosomal RNA^3,4 and inducing apoptosis in virus-infected cells^5,6. RNase L is suggested to have antitumor effects, possibly through its pro-apoptotic activity⁷, and mutations in the RNASEL gene are associated with prostate cancer risk and progression^8,9.

RNase L is highly expressed in the spleen and thymus, followed by prostate, testis, uterus, small intestine, colon, and peripheral blood leukocytes.

1. Zhou A, et al. (2005) J Interferon Cytokine Res. 25(10):595-603
2. Silverman RH. (2007) Cytokine Growth Factor Rev. 18(5-6):381-8
3. Wreschner DH, et al. (1981) Nucleic Acids Res. 9(7):1571-81
4. Cooper DA, et al. (2014) Nucleic Acids Res. 42(8):5202-16
5. Castelli JC, et al. (1997) J Exp Med. 186(6):967-72
6. Zhou A, et al (1997) EMBO J. 16(21):6355-63
7. Xiang Y, et al. (2003) Cancer Res. 63(20):6795-801
8. Meyer MS, et al. (2010) Carcinogenesis. 31(9):1597-603
9. Silverman RH. (2003) Biochemistry. 42(7):1805-12